Compare ONEOK Inc. Common Stock (OKE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance

ONEOK (OKE) trades at $93.38, up 1.48% with a bullish technical outlook and strong fundamental performance. The stock shows solid valuation metrics with P/E of 16.13 and P/S of 1.5, supported by $33.63B revenue and $3.39B net income in 2025. Recent acquisition of Brazos Midstream's assets for $4.425B expands Permian Basin presence, while quarterly dividends remain steady at $1.07 per share.

Outlook remains positive with analyst consensus target of $98.55 (5.5% upside) and no sell ratings. Key risks include integration of recent acquisition and commodity price exposure. Earnings beat expectations in 2 of last 3 quarters, with Q3 2026 results due October 27 providing next catalyst.

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.